Dr. Robert Fremeau

Dr. Robert Fremeau founded BrainStorm Therapeutics to discover and develop breakthrough medicines to transform the lives of the millions of patients suffering from devastating neurological disorders. With over 25 years of experience in academia and industry he is an accomplished scientist with a proven track record of scientific innovation and program leadership at the intersection of target validation, preclinical translation, and clinical development. At BrainStorm Therapeutics, Dr. Fremeau is developing a proprietary platform combining patient-derived brain organoid disease models and advanced data analytics to discover therapeutic candidates that halt, prevent, or reverse critical molecular events in the brain that lead to synaptic network dysfunction and neurodegeneration.

Prior to BrainStorm Therapeutics, Dr. Fremeau was the Chief Scientific Officer at Vyant Bio, where he spearheaded Vyant Bio’s transition from an organoid manufacturing and services company to a drug discovery platform company with a promising pipeline of repurposing and novel drug candidates for rare CNS genetic disorders including Rett syndrome and CDKL5 deficiency disorder (CDD). Under Dr. Fremeau’s leadership, the Vyant team discovered repurposing candidates for Rett syndrome with a differentiated mechanism of action, that are advancing to a Phase 2 clinical trial funded by the Department of Defense.

Prior to Vyant Bio, Bob worked in the biopharmaceutical sector investigating the role of neuroinflammation in severe diseases of the central nervous system at CAMP4 Therapeutics, AegisCN, and Rapid Pharma/Resolute Bio. From 2004 to 2014 he worked at Amgen. As a Scientific Director, he transformed the capabilities and growth horizons of Amgen’s Neuroscience research operations and served as the cross-functional team leader for the two largest small molecule drug discovery programs in the company.

Before moving to the biopharmaceutical sector, Dr. Fremeau led a productive academic career at the University of California San Francisco and Duke University Medical School where he made seminal contributions to the first molecular and functional characterization of the receptors and transporters for the biogenic amine and amino acid neurotransmitters. Dr. Fremeau’s diverse research efforts across industry and academia have led to the publication of over 65 peer-reviewed publications in top-tier scientific journals and multiple patents. He has served on the Editorial Board of Molecular Pharmacology and as a grant reviewer for NIH and NSF.

Dr. Fremeau conducted his postdoctoral fellowship in Molecular Neurobiology at Columbia University College of Physicians and Surgeons. He received his PhD in Biochemistry from the George Washington University Medical Center.